Cyclacel Pharmaceuticals, Inc. (CYCC)
NASDAQ: CYCC · Real-Time Price · USD
0.2811
+0.0521 (22.75%)
At close: Apr 25, 2025, 4:00 PM
0.2650
-0.0161 (-5.73%)
After-hours: Apr 25, 2025, 5:05 PM EDT

Cyclacel Pharmaceuticals Stock Forecast

CYCC's stock price has decreased by -87.78% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 1 analyst with a 12-month price forecast for Cyclacel Pharmaceuticals stock has a target of 11, which predicts an increase of 3,813.20% from the current stock price of 0.28.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $11 $11 $11 $11
Change +3813.2% +3813.2% +3813.2% +3813.2%
* Price targets were last updated on May 3, 2024.

Analyst Ratings

According to 1 stock analyst, the rating for Cyclacel Pharmaceuticals is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Dec '23Jan '24Feb '24Mar '24Apr '24May '24
Strong Buy 111111
Buy 111110
Hold 111110
Sell 000000
Strong Sell 000000
Total 333331

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Roth MKM
Roth MKM
Strong Buy
Maintains
$21$11
Strong Buy Maintains $21$11 +3,813.20% May 3, 2024
Brookline Capital
Brookline Capital
Hold
Downgrades
n/a
Hold Downgrades n/a n/a Dec 19, 2023
Roth MKM
Roth MKM
Strong Buy
Maintains
$16$21
Strong Buy Maintains $16$21 +7,370.65% Dec 19, 2023
Oppenheimer
Oppenheimer
Buy
Maintains
$120
Buy Maintains $120 +42,589.43% May 25, 2023
Oppenheimer
Oppenheimer
Buy
Maintains
$150$120
Buy Maintains $150$120 +42,589.43% Mar 7, 2023
More Analyst Ratings

Financial Forecast

Revenue This Year
102.00K
from 43.00K
Increased by 137.21%
Revenue Next Year
102.00K
from 102.00K
EPS This Year
-1.20
from -2.09
EPS Next Year
-1.14
from -1.20
Fiscal Year FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2020 Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
---420.00K43.00K102.00K102.00K82.19M
Revenue Growth
-----89.76%137.21%-80,482.35%
EPS
-51.30-31.35-28.52-26.75-2.09-1.20-1.143.74
EPS Growth
--------
Forward PE
-------0.08
No. Analysts
-----333
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 202520262027
High 105,000 105,000 84.6M
Avg 102,000 102,000 82.2M
Low 98,000 98,000 79.0M

Revenue Growth

Revenue Growth 202520262027
High
144.2%
2.9%
82,852.0%
Avg
137.2%
-
80,482.4%
Low
127.9%
-3.9%
77,321.6%

EPS Forecast

EPS 202520262027
High -1.24 -1.18 3.85
Avg -1.20 -1.14 3.74
Low -1.16 -1.10 3.60

EPS Growth

EPS Growth 202520262027
High - - -
Avg - - -
Low - - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.